New hope for hard-to-treat leukemia: drug combo enters phase 2 trial

NCT ID NCT05442216

Recruiting now Disease control Sponsor: Joshua Zeidner Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests a new combination of three drugs (tagraxofusp, azacitidine, and venetoclax) for people with a type of acute myeloid leukemia (AML) that has returned or not responded to previous treatment. The goal is to see if this combination can help more patients achieve remission. About 53 adults will take part, receiving the drugs in 28-day cycles with regular bone marrow checks to measure response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

AdventHealth Orlando
RECRUITING

Orlando, Florida, 32803, United States
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
RECRUITING

Winston-Salem, North Carolina, 27157, United States
Lifespan Health System Rhode Island Hospital
RECRUITING

Providence, Rhode Island, 46278, United States
Penn Medicine Abramson Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Roswell Park Cancer Institute
RECRUITING

Buffalo, New York, 14263, United States
University of Miami
RECRUITING

Miami, Florida, 33136, United States
University of North Carolina at Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.